184 filings
Page 5 of 10
6-K
eqbpqg47qj21btyt6
11 Jan 21
InflaRx Provides Update on Vilobelimab (IFX-1) Development
7:30am
6-K
9b3m8qzq49qp12lxcs
5 Jan 21
InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis
7:30am
6-K
h1n swn0h5dv
29 Oct 20
Current report (foreign)
7:05am
6-K
rje6wp1u
17 Sep 20
InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer
7:31am
6-K
598x0bw 65og2
14 Sep 20
InflaRx Announces Initiation of Phase III Part of Phase II/III Clinical Trial with IFX-1 in Severe COVID-19 Induced Pneumonia
7:36am
6-K
j4lasr7 ynnl8g671
6 Aug 20
InflaRx to Present at Upcoming Virtual Investor Events
7:35am
S-8
32gp1r4ae2cxt
30 Jul 20
Registration of securities for employees
8:39am
6-K
7l2pot6jfz 51g
30 Jul 20
Current report (foreign)
7:36am
6-K
flnlvnfh ahmfw7y
21 Jul 20
InflaRx Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced Pneumonia
7:35am
424B5
s61kfe
20 Jul 20
Prospectus supplement for primary offering
9:21am
6-K
uc10hdstc 0h
20 Jul 20
from 6-K
9:02am
EFFECT
tfzn adjpsxzu03m4q
20 Jul 20
Notice of effectiveness
12:15am
6-K
i86aoc
16 Jul 20
Current report (foreign)
4:06pm
F-3/A
6irng gektoigetzu0
16 Jul 20
Shelf registration (foreign) (amended)
9:33am
CORRESP
nozpqmpzmoqlkff4cl
16 Jul 20
Correspondence with SEC
12:00am
UPLOAD
yvudsl565lpv 2cylvd
15 Jul 20
Letter from SEC
12:00am
F-3
bbqedu 8agy9tf
8 Jul 20
Shelf registration (foreign)
12:00am
6-K
zng8pyuiejpl
30 Jun 20
Current report (foreign)
6:38am
6-K
ab70cmw
17 Jun 20
InflaRx Reports Encouraging Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II/III Trial of IFX-1 in COVID-19
7:30am
6-K
ziyo1 tvx0gfm8ywvr
21 May 20
Current report (foreign)
8:09am